Advanced

Manipulation of BCG vaccine: a double-edged sword.

Singh, Vipul LU ; Srivastava, R and Srivastava, B S (2016) In European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 35(4). p.535-543
Abstract
Mycobacterium bovis Bacillus Calmette-Guérin (BCG), an attenuated vaccine derived from M. bovis, is the only licensed vaccine against tuberculosis (TB). Despite its protection against TB in children, the protective efficacy in pulmonary TB is variable in adolescents and adults. In spite of the current knowledge of molecular biology, immunology and cell biology, infectious diseases such as TB and HIV/AIDS are still challenges for the scientific community. Genetic manipulation facilitates the construction of recombinant BCG (rBCG) vaccine that can be used as a highly immunogenic vaccine against TB with an improved safety profile, but, still, the manipulation of BCG vaccine to improve efficacy should be carefully considered, as it can bring... (More)
Mycobacterium bovis Bacillus Calmette-Guérin (BCG), an attenuated vaccine derived from M. bovis, is the only licensed vaccine against tuberculosis (TB). Despite its protection against TB in children, the protective efficacy in pulmonary TB is variable in adolescents and adults. In spite of the current knowledge of molecular biology, immunology and cell biology, infectious diseases such as TB and HIV/AIDS are still challenges for the scientific community. Genetic manipulation facilitates the construction of recombinant BCG (rBCG) vaccine that can be used as a highly immunogenic vaccine against TB with an improved safety profile, but, still, the manipulation of BCG vaccine to improve efficacy should be carefully considered, as it can bring in both favourable and unfavourable effects. The purpose of this review is not to comprehensively review the interaction between microorganisms and host cells in order to use rBCG expressing M. tuberculosis (Mtb) immunodominant antigens that are available in the public domain, but, rather, to also discuss the limitations of rBCG vaccine, expressing heterologous antigens, during manipulation that pave the way for a promising new vaccine approach. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
volume
35
issue
4
pages
535 - 543
publisher
Springer
external identifiers
  • pmid:26810060
  • scopus:84955279310
  • wos:000373300000003
ISSN
1435-4373
DOI
10.1007/s10096-016-2579-y
language
English
LU publication?
yes
id
82f278ad-0486-4866-a2c0-42d6844ba887 (old id 8573693)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26810060?dopt=Abstract
date added to LUP
2016-02-04 21:27:24
date last changed
2017-09-03 04:55:30
@article{82f278ad-0486-4866-a2c0-42d6844ba887,
  abstract     = {Mycobacterium bovis Bacillus Calmette-Guérin (BCG), an attenuated vaccine derived from M. bovis, is the only licensed vaccine against tuberculosis (TB). Despite its protection against TB in children, the protective efficacy in pulmonary TB is variable in adolescents and adults. In spite of the current knowledge of molecular biology, immunology and cell biology, infectious diseases such as TB and HIV/AIDS are still challenges for the scientific community. Genetic manipulation facilitates the construction of recombinant BCG (rBCG) vaccine that can be used as a highly immunogenic vaccine against TB with an improved safety profile, but, still, the manipulation of BCG vaccine to improve efficacy should be carefully considered, as it can bring in both favourable and unfavourable effects. The purpose of this review is not to comprehensively review the interaction between microorganisms and host cells in order to use rBCG expressing M. tuberculosis (Mtb) immunodominant antigens that are available in the public domain, but, rather, to also discuss the limitations of rBCG vaccine, expressing heterologous antigens, during manipulation that pave the way for a promising new vaccine approach.},
  author       = {Singh, Vipul and Srivastava, R and Srivastava, B S},
  issn         = {1435-4373},
  language     = {eng},
  month        = {01},
  number       = {4},
  pages        = {535--543},
  publisher    = {Springer},
  series       = {European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology},
  title        = {Manipulation of BCG vaccine: a double-edged sword.},
  url          = {http://dx.doi.org/10.1007/s10096-016-2579-y},
  volume       = {35},
  year         = {2016},
}